Palbociclib is used for the treatment of HR-positive and HER2-negative breast cancer. Palbociclib was developed by Warner-Lambert Company Llc.
The API has now reached off-patent status, after being launched in 2015.

The information provided above is sourced from Chemrobotics PharmaVetPat https://chemroboticspharma.com/pharmVetPat
to find out more, including patent landscape and routes of synthesis, please contact our sales team.

According to PharmaTrade, Palbociclib was exported from India in 2023 , with an average price over the period of $6360 /kg.
The key suppliers were Cdymax Pharma, with a focus on markets in MEA.

For enquiries regarding more detailed trade data of Palbociclib and many others, contact info@pharmacheminvestor.com